Key result
Resolute zotarolimus-eluting stents in small coronary vessels yielded similar 2-year target lesion failure rates compared to large vessels (10.1% vs. 8.7%; P=0.54).
Why the study?
Does the Resolute zotarolimus-eluting stent provide comparable clinical outcomes in small vessels compared to large vessels in patients with coronary artery disease?
Observational (n=5,130)
Yes
Does the Resolute zotarolimus-eluting stent provide comparable clinical outcomes in small vessels compared to large vessels in patients with coronary artery disease?
The Resolute zotarolimus-eluting stent provides acceptable 2-year clinical outcomes in small vessels, comparable to its performance in large vessels, regardless of diabetes status.
Supports Resolute stent use in small vessels; extends observational data but leaves open randomized confirmation.
BACKGROUND: Drug eluting stents for the treatment of small vessel coronary artery disease have traditionally yielded inferior clinical outcomes compared to the use of DES in large vessels. The benefit of the second-generation Resolute zotarolimus-eluting stent (R-ZES) in small vessels was examined. METHODS: Two-year clinical outcomes from five combined R-ZES studies were compared between patients with small (reference vessel diameter [RVD] ≤2.5 mm; n = 1,956) and large (RVD >2.5 mm; n = 3174) vessels. RESULTS: Despite a higher incidence of comorbidities in the small vessel group, there was no significant difference in target lesion failure (TLF) (10.1% vs. 8.7%; P = 0.54) at 2 years. When the subgroup of patients with diabetes was examined (n = 1,553) there was no significant difference in 2-year TLF in small compared to large vessels (11.2% vs. 11.1%; P = 0.17). Similarly, within the small vessel cohort, no significant difference was seen regarding TLF at 2 years between people with and without diabetes (11.2% vs 9.6%; P = 0.28). CONCLUSION: When used for the treatment of small vessels, the R-ZES appears to provide acceptable clinical results at 2 years when compared to its performance in large vessels.
No takes yet. Share an insight, caveat, or question.
Caputo et al. (2014) conducted an observational in small vessel coronary artery disease (n=5,130). Resolute zotarolimus-eluting stent in small vessels (RVD ≤2.5 mm) vs. Resolute zotarolimus-eluting stent in large vessels (RVD >2.5 mm) was evaluated on target lesion failure (TLF) at 2 years (p=0.54). Resolute zotarolimus-eluting stents in small coronary vessels yielded similar 2-year target lesion failure rates compared to large vessels (10.1% vs. 8.7%; P=0.54).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: